INDOXACARB - INCHEM
315INDOXACARBFirst draft prepared byU. Mueller1 and Angelo Moretto21 Office of Chemical Safety, Therapeutic Goods Administration, Canberra, ACT, Australia; and 2 Dipartimento Medicina Ambientale e Sanit Pubblica, Universit di Padova, Padova, Italy 316Evaluation for acceptable daily 316Biochemical aspects ........................................ ............................... 316Absorption, distribution and 316Biotransformation ........................................ ......................... 319Toxicological 319Acute 319Oral 319Dermal administration ........................................ .......... 319Exposure by inhalation ........................................ ......... 320Dermal and ocular irritation ........................................ . 320Dermal sensitization ........................................ ............. 320Short-term studies of 323Long-term studies of toxicity and 334Reproductive 336Multigeneration studies.
INDOXACARB 31 –3 JMPR 2005 317 Although only sparingly soluble in aqueous media (0.2 g/ml), racemic indoxacarb (DPX-JW062 or DPX-MP062) was suspended in polyethylene glycol (PEG-400) to give a fixed dosage
Download INDOXACARB - INCHEM
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: